Combination of Tagrisso and chemo improves lung cancer outcomes.
TL;DR Summary
AstraZeneca's Tagrisso-chemo combination has shown statistically significant and clinically meaningful improvement in progression-free survival compared to Tagrisso as a monotherapy in late-stage lung cancer patients, according to the Phase III FLAURA2 trial. The trial tested the combination in late-stage patients with locally advanced or metastatic EGFR-mutated non-small cell lung cancer.
- AstraZeneca: Tagrisso-chemo combo improved progression-free survival in late-stage lung cancer trial – Endpoints News Endpoints News
- AZ's Tagrisso plus chemo triumphs in EGFR-mutated lung cancer FiercePharma
- AstraZeneca Tagrisso chemo combo cuts risk of lung cancer progression Seeking Alpha
- Osimertinib/Chemo Improves Survival Vs Osimertinib in EGFR+ NSCLC Cancer Network
- Immunotherapy Plus Chemo Improves Quality of Life in NSCLC Medscape
Reading Insights
Total Reads
0
Unique Readers
0
Time Saved
7 min
vs 7 min read
Condensed
96%
1,351 → 50 words
Want the full story? Read the original article
Read on Endpoints News